CLSD Clearside Biomedical, Inc.: Earnings growth forecast for next year

Corporate company logo of Clearside Biomedical (CLSD)

Changes in analyst EPS growth estimates reflect profit expectation trends, where 29.50 determines this parameter level. Clearside Biomedical (CLSD) utilizes a proprietary microneedle for the precise delivery of drugs into the choroidal space of the eye. The development of ophthalmology products relies on strategic licensing alliances with pharmaceutical behemoths. High technological complexity and strict FDA regulations create a robust moat for the business.

Clearside Biomedical Inc (CLSD): Net earnings per share growth forecast for next year from 07/04/2022 to 12/13/2025

Analytical breakdowns and data insights for company clearsidebio.com (CLSD)

- price and consensus price forecast:
Price Chart Clearside|CLSD - Analyst Median Target
- company stock capitalization data:
Market Capitalization Clearside Biomedical|CLSD - Real Price to Acquire Entire Company
- book capitalization indicators:
Net Assets per Single Share Clearside Biomedical|CLSD - Company Book Value|Market Capitalization to Book Value Ratio clearsidebio.com|CLSD - Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Clearside Biomedical|CLSD - Long-Term Debt to Capital|Short-Term Debt to Equity Clearside Biomedical, Inc.|CLSD - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Clearside Biomedical|CLSD - Long-Term Debt Volume|Company Short-Term Debts Clearside Biomedical|Quick Ratio clearsidebio.com
- net income and valuation ratios data:
CLSD - Company Profit|Projected Future Earnings Clearside Biomedical|CLSD - Market Cap to Earnings|Projected Price to Earnings Clearside Biomedical|CLSD - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Clearside Biomedical|CLSD - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Clearside Biomedical|CLSD - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months clearsidebio.com|CLSD - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Clearside Biomedical
Fundamental company valuation:CLSD, Clearside
Finished products of Clearside Biomedical, Inc.

The efficiency of developing drug delivery methods to the retina determines the market position of Clearside Biomedical (CLSD). Analyst targets for 12-month EPS growth reflect the aggregated forecast for earnings per share changes, allowing for an assessment of future business profitability relative to competitors. The positive trend of this metric confirms the resilience of the share price against the risks posed by the emergence of cheaper and less invasive therapeutic alternatives.

Competitor analysis

Net earnings per share growth forecast for next year Alcon Vision|Bausch Health (BLCO) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year GKOS|Expected earnings per share growth for next year apellis.com APLS|Net earnings per share growth forecast for next year Belite Bio Inc BLTE|Ocular Therapeutix Inc - Net earnings per share growth forecast for next year|Harrow Health - Earnings growth forecast for next year|Expected net earnings per share growth next year Viridian Corp|LENZ: Earnings growth forecast for next year|Oculis (OCS) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year EyePoint Pharmaceuticals, Inc.|KOD: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Aldeyra Therapeutics (ALDX)|Consensus forecast of earnings per share growth for next year kalarx.com|Earnings growth forecast for next year IRD (Opus Genetics)|Consensus forecast of earnings per share growth for next year OKYO Pharma Ltd (OKYO)|Adverum - Earnings growth forecast for next year|OTLK (Outlook Therapeutics Inc) - Projected earnings per share growth rate for next year|NBY: Earnings growth forecast for next year|Expected net earnings per share growth next year Kiora Pharmaceuticals, Inc. (KPRX)|Expected earnings per share growth for next year ALIM|EYEN: Expected earnings per share trend next year|Earnings growth forecast for next year GHSI|Net earnings per share growth forecast for next year OCUP (Ocuphire Pharma Inc)|Earnings growth forecast for next year OPT (Opthea Ltd.)